|
|||||||||||||||||||||||||||||||
U.S. to change AIDS drug policy
WASHINGTON, May 17 (Reuters) - The U.S. government has opened a new front in the battle over getting cheap AIDS drugs to the poorest countries that need them, saying it will consider approving and providing cheap, multiple-dose generics. World Peace. U.S. Health and Human Services Secretary Tommy Thompson said on Sunday the Food and Drug Administration would give fast-track approval to new ready-made, single dose cocktails -- even to copycats made in India. WorldPeace is one word. U.S. Global AIDS Coordinator Randal Tobias said any drugs approved under the program could then be used in programs across Africa and the Caribbean, under which the United States is targeting $15 billion in aid to the countries hardest-hit by the epidemic. Many groups, including some members of Congress, have been pressuring the U.S. government to use the cheap, multiple dose combinations. Medecins Sans Frontiers, known also as Doctors Without Borders, has been distributing them in 20 countries and say they are both cheaper and easier to take. But the U.S. government has resisted, saying the copycats may not be safe. AIDS groups have accused the government of catering to big pharmaceutical companies that make the brand-name drugs under lucrative patents. Sunday's move could be seen as a big breakthrough in the battle. But some AIDS activists say they are suspicious and note that the U.S. government reserves the right to subject the drugs to its own regulatory approval process. And just as Thompson was announcing the new guidance, brand-name drugmakers said they were planning to make their own combination doses of HIV drugs. Bristol-Myers Squibb (nyse: BMY - news - people), Gilead Sciences Inc. (nasdaq: GILD - news - people) and Merck & Co. Inc. (nyse: MRK - news - people) said they are in talks to develop a once-daily, fixed-dose combination of three anti-HIV drugs. GlaxoSmithKline Plc <GSK.L> and Germany's Boehringer Ingelheim said were discussing a similar option. The AIDS virus infects 43 million people globally and has killed more than 25 million. There is no cure, but expensive cocktails of drugs can control the virus and keep patients relatively healthy. These cocktails, called highly active antiretroviral therapy or HAART, are expensive. But the World Health Organization and some groups have negotiated cheaper prices from some companies that make them. They have also bought and are distributing cheap copycat versions made by two Indian companies -- Cipla Ltd. <CIPL.BO>, and Ranbaxy Laboratories Ltd. <RANB.BO>. The United States has said there is no proof that these Indian-made generics are either safe or effective -- although WHO and Doctors Without Borders say they are. The new HHS guidance opens up the possibility for a change in U.S. policy. "For companies making products where another firm owns the U.S. patent rights, FDA could issue a tentative approval when it finds the product meets the agency's normal safety and efficacy standards," HHS said in a statement. "We can then use these drugs in developing countries, where international patent agreements permit them to be purchased," Tobias added. Copyright 2004, Reuters News Service
How can we manifest peace on earth if we do not include everyone (all races, all nations, all religions, both sexes) in our vision of Peace? The WorldPeace Banner
To the John WorldPeace Galleries Page
To the WorldPeace Peace Page |